AKBA
Akebia Therapeutics, Inc.Data: 2026-09-04
Quick Stats
Sep 04, 202643.6
AI Score
HOLD1.17
Volume Ratio
TBA
Next Earnings
14
+ve Days (30d)
16
-ve Days (30d)
AKBA Price vs Max Options Open Interest
How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.
AKBA Max Change In Options Open Interest
How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.
AKBA Options - Sort by Max open Interest (near term)
5th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AKBA Daily Out of Money Options - Sort by Max open Interest (near term)
5th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AKBA Daily In the Money Options - Sort by Max open Interest (near term)
5th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AKBA Most Active Options by Volume(near term)
5th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
AKBA Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
AKBA Stock Summary
Last updated Sep 04, 2026
AKBA is currently trading at $0.9747, positioned below its 200-day moving average of $1.29, suggesting bearish momentum. The stock has a 52-week range of $0.814 to $3.2.
Technical Analysis: The 50-day moving average stands at $1.13, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 48.087, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.175, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates AKBA at 43.6/100 with a HOLD recommendation.
AKBA (Akebia Therapeutics, Inc.) Indicators
Last updated Sep 04, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 48.087 |
| CMF (20) | 0.175 |
| ROC (10) | 7.512 |
| ADX (14) | 22.704 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.037 |
| AROONOSC (14) | 85.714 |
| WILLAMS %R (14) | -20.547 |
| MFI (14) | 70.999 |
Akebia Therapeutics, Inc. is below both the 50 Day and 200 Day SMA which is considered Bearish.
AKBA Moving Averages Analysis
AKBA (Akebia Therapeutics, Inc.) Simple Moving Averages
Moving Averages are last updated Sep 04, 2026
| Days | MA |
|---|---|
| 10 | 0.94 |
| 20 | 0.91 |
| 30 | 1.01 |
| 50 | 1.13 |
| 100 | 1.14 |
| 200 | 1.29 |
AKBA Fundamental Analysis
| P/E (Forward) | 28.7356 |
| P/E (Trailing) | -- |
| Market Cap ($) | 272.5 million |
| Earnings/Share ($) | -0.12 |
| Net Profit Margin (%) | -0.1354 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.16 |
| EPS Estimate Next Year ($) | -0.33 |
| WallStreet Target Price ($) | 3.80 |
| Most Recent Quarter |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.